{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:40:51Z","timestamp":1789839651475,"version":"4.0.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy is an effective treatment for refractory hematologic malignancies; however, gastrointestinal adverse events (GI-AEs) are increasingly recognized as its use expands. We identified 6 patients with GI-AEs following CAR-T therapy over a 5-year period at our institution and conducted a comprehensive PubMed literature review to characterize histopathologic patterns and highlight differential diagnostic considerations. In the institutional cohort, the colon was most frequently involved (83%), followed by the small bowel (67%) and stomach (33%). Most patients developed watery diarrhea (83%) with negative infectious studies. Symptom onset occurred at a median of 107 days after infusion (range, 19 to 236\u00a0d). Twenty-one gastrointestinal biopsies were evaluated; 15 (71%) showed histologic abnormalities. Four histologic patterns were identified: active inflammation (33%), chronic active inflammation (27%), apoptosis-predominant injury (27%), and chronic inflammation (13%). Crypt epithelial apoptosis or intraepithelial apoptotic bodies were present in 67% of biopsies. Site-specific patterns included active colitis in the colon, chronic or chronic active duodenitis in the duodenum, apoptosis-predominant ileal injury, and active gastritis in the stomach. The literature review identified 22 additional patients, with histopathologic data available in 21 cases. Findings overlapped substantially with the institutional cohort and most commonly involved the colon and small intestine, with heterogeneous clinical outcomes. Overall, CAR-T\u2013associated GI-AEs demonstrate reproducible yet nonspecific clinicopathologic features that overlap with immune-mediated, drug-related, infectious, and inflammatory conditions, necessitating careful clinicopathologic correlation and exclusion of alternative etiologies.<\/jats:p>","DOI":"10.1097\/pas.0000000000002544","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:00:22Z","timestamp":1776052822000},"page":"739-757","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Histopathologic Features of Chimeric Antigen Receptor (CAR) T-cell Therapy-associated Gastrointestinal Mucosal Injury"],"prefix":"10.1097","volume":"50","author":[{"given":"Ihsan","family":"Baroudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Abukhiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reetesh","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akila","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"R1-20260617","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"key":"R2-20260617","doi-asserted-by":"crossref","first-page":"e948125","DOI":"10.12659\/MSM.948125","article-title":"A review of CAR T cells and adoptive T-cell therapies in lymphoid and solid organ malignancies","volume":"31","author":"Parums","year":"2025","journal-title":"Med Sci Monit"},{"key":"R3-20260617","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"key":"R4-20260617","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/ibd\/izaa320","article-title":"Colitis after CAR T-cell therapy for refractory large B-cell lymphoma responds to anti-integrin therapy","volume":"27","author":"Hashim","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"R5-20260617","doi-asserted-by":"crossref","first-page":"1149450","DOI":"10.3389\/fonc.2023.1149450","article-title":"Case report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma","volume":"13","author":"Zundler","year":"2023","journal-title":"Front Oncol"},{"key":"R6-20260617","doi-asserted-by":"crossref","first-page":"17588359241309824","DOI":"10.1177\/17588359241309825","article-title":"Severe refractory colitis after intraperitoneal infusion of CEA-directed CAR T cells in patients with colorectal cancer","volume":"16","author":"Ye","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"R7-20260617","doi-asserted-by":"crossref","first-page":"17588359251320736","DOI":"10.1177\/17588359251320736","article-title":"CART-induced eosinophilic colitis with good response to corticosteroids and infliximab: a case report","volume":"17","author":"Coleman","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"R8-20260617","doi-asserted-by":"crossref","first-page":"105791","DOI":"10.1016\/j.humpath.2025.105791","article-title":"Chimeric antigen receptor (CAR) T-cell therapy-related gastrointestinal toxicity: histologic features and morphologic mimics","volume":"158","author":"Karimi","year":"2025","journal-title":"Hum Pathol"},{"key":"R9-20260617","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.humpath.2009.04.001","article-title":"Pathology of graft-versus-host disease in the gastrointestinal tract","volume":"40","author":"Washington","year":"2009","journal-title":"Hum Pathol"},{"key":"R10-20260617","doi-asserted-by":"crossref","first-page":"571","DOI":"10.5858\/arpa.2020-0070-RA","article-title":"Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy","volume":"145","author":"Patil","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"R11-20260617","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5493\/wjem.v11.i6.79","article-title":"Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: a comprehensive review","volume":"11","author":"Li","year":"2021","journal-title":"World J Exp Med"},{"key":"R12-20260617","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/modpathol.2009.44","article-title":"Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil","volume":"22","author":"Selbst","year":"2009","journal-title":"Mod Pathol"},{"key":"R13-20260617","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","article-title":"Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy","volume":"390","author":"Ozdemirli","year":"2024","journal-title":"N Engl J Med"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:07:02Z","timestamp":1785784022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002544"}},"subtitle":["A Case Series and Review of Literature"],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002544","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"2025-07-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}